Celldex price target raised to $37 from $35 at Wells Fargo

Wells Fargo raised the firm’s price target on Celldex to $37 from $35 and keeps an Equal Weight rating on the shares. The firm thinks there is modest upside for shares on barzo’s upcoming 52-week data plus data from briquilimab, both of which are in the second half of 2024. That said, Wells remains on the sidelines given the lack of significant catalysts in the medium-term.